CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA

临床试验：磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA

• 批准号: 7952127
• 负责人: MARTIN M LEWINTER
• 金额: $ 0.28万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952127
• 关键词: Chronic; Clinical; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diastolic heart failure; Double-Blind Method; EFRAC; Exercise; Funding; Grant; Heart failure; Institution; Measures; Patients; Performance; Placebos; RELA gene; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; improved; inhibitor/antagonist; placebo controlled study; sildenafil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition (sildenafil 80 mg tid for 24 weeks) improves exercise capacity and clinical status in patients with heart failure and normal ejection fraction. This study also measures the effect of this therapy on key pathophysiological parameters which are postulated to impact clinical status and exercise performance in diastolic heart failure. 120 patients will be studied. Approximately 10 here at FAHC. The primary endpoint is change in exercise capacity as assessed by peak VO2 after 24 weeks of double-blinded treatment PDE-5 inhibitor or placebo.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项双盲、安慰剂对照研究，测试以下假设：慢性 PDE-5 抑制（西地那非 80 毫克，每日一次，持续 24 周）可改善心力衰竭和射血分数正常患者的运动能力和临床状态。 这项研究还测量了该疗法对关键病理生理参数的影响，这些参数被认为会影响舒张性心力衰竭的临床状态和运动表现。 将研究 120 名患者。 FAHC 大约有 10 个。 主要终点是 PDE-5 抑制剂或安慰剂双盲治疗 24 周后通过峰值摄氧量评估的运动能力变化。